While agents like imatinib and rapamycin show favorable vascular effects with limited vascular toxicity in preclinical studies, others, such as VEGF inhibitors or certain second-generation TKIs carry additional risks of hypertension, thrombosis, and endothelial dysfunction, which can paradoxically worsen atherosclerosis progression. The gene discussed is VEGFA; the disease is hypertensive disorder.